超150个管线,4款已上市!当下,HER2 ADC赛道竞争十分激烈。数据显示,4款已经上市的产品包括恒瑞医药的瑞康曲妥珠单抗、阿斯利康的德曲妥珠单抗、罗氏的恩美曲妥珠单抗、荣昌生物的维迪西妥单抗。其中,恒瑞医药的瑞康曲妥珠单抗于2025年5月,获批上市,用于治疗存在HER2(ERBB2)激活突变且既往接受过至少一种系统治疗的不可切除的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者。据悉,截至...
Source Link超150个管线,4款已上市!当下,HER2 ADC赛道竞争十分激烈。数据显示,4款已经上市的产品包括恒瑞医药的瑞康曲妥珠单抗、阿斯利康的德曲妥珠单抗、罗氏的恩美曲妥珠单抗、荣昌生物的维迪西妥单抗。其中,恒瑞医药的瑞康曲妥珠单抗于2025年5月,获批上市,用于治疗存在HER2(ERBB2)激活突变且既往接受过至少一种系统治疗的不可切除的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者。据悉,截至...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.